

IDS/ #10
3/13/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Thomas Teufel Examiner: Unassigned
Serial No.: Unassigned Group Art Unit: Unassigned
Filed: Herewith Docket: 381-86
For: TREATMENT OF
HYPERPROLIFERATIVE
DISEASES WITH EPIDERMAL
GROWTH FACTOR
RECEPTOR ANTAGONISTS

10841 U.S. PRO
09/09/00
09/09/00
JC 635974

Assistant Commissioner for Patents
Washington, DC 20231

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.

20231 on August 9, 2000

Dated: 8/9/2000

J. Peterson

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

| <u>PATENTEE</u> | <u>PATENT NO.</u> | <u>ISSUE DATE</u> |
|------------------------|--------------------------|--------------------------|
| Boss et al. | 4,816,397 | March 28, 1989 |
| Levitzki et al. | 5,196,446 | March 23, 1993 |
| Strayer | 5,550,114 | August 27, 1996 |
| Spada et al. | 5,646,153 | July 8, 1997 |

| | | |
|--------------------|-----------|--------------------|
| Spada et al. | 5,656,655 | August 12, 1997 |
| Bridges et al. | 5,679,683 | October 21, 1997 |
| Chen et al. | 5,789,427 | August 4, 1998 |
| Ullrich et al. | 5,851,999 | December 22, 1998 |
| Rockwell et al. | 5,861,499 | January 19, 1999 |
| Morgan, Jr. et al. | 5,869,465 | February 9, 1999 |
| Bennett et al. | 5,914,269 | June 22, 1999 |
| Davis et al. | 5,925,566 | July 20, 1999 |
| Rockwell et al. | 5,955,311 | September 21, 1999 |
| McMahon et al. | 6,004,967 | December 21, 1999 |

FOREIGN PATENT DOCUMENTS

| <u>COUNTRY</u> | <u>PATENT NO.</u> | <u>ISSUE DATE</u> |
|----------------|-------------------|-------------------|
| Europe | PCT/AU99/00420 | May 31, 1999 |

NON-PATENT PUBLICATIONS


1. Green, Larry L, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," *Journal of Immunological Methods*, # 231:11-23 (1999).
2. Jost, et al., "A Central Role of Bcl-X_L in the Regulation of Keratinocyte Survival by Autocrine EGFR Ligands," *The Journal of Investigative Dermatology*, # 112:443-449 (1999).
3. Kao, et al., "Comparison of the Effect of 8-Methoxysoralen (8-MOP) plus UVA (PUVA) on Human Melanocytes in Vitiligo Vulgaris and *In Vitro*," *The Journal of Investigative Dermatology*, # 98(5):734-740 (1992).

4. Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," *Experimental Dermatology*, #6:214-221 (1997).
5. Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," *Brief Definitive Report*, # 167:670-675 (1998).
6. Fransson et al., "Epidermal growth in the skin equivalent," *Archives of Dermatological Research*, # 284:343-348 (1992).
7. Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," *Journal of the American Academy of Dermatology*, # 40:901-9 (1999).
8. Varani, et al., "Human Psoriatic Skin in Organ Culture: Comparison with Normal Skin Exposed to Exogenous Growth Factors and Effects of an Antibody to the EGF Receptor," *Pathobiology*, # 66:253-259 (1998).
9. Elder, et al., "Human Severe Combined Immunodeficiency Due to a Defect in ZAP-70, a T Cell Tyrosine Kinase," *Science*, # 264: (1994).
10. Dvir, et al., "The Inhibition of EGF-dependent Proliferation of Keratinocytes by Tyrphostin Tyrosine Kinase Blockers," *The Journal of Cell Biology*, # 113:4 (1991).
11. Grossman, et al., "Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes," *Proc. Natl. Acad. Sci. USA*, # 86:6367-6371 (1989).
12. Fry, et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," *Science*, # 265:1093-1095 (1994).
13. Vassar, et al., "Transgenic mice provide new insights into the role of TGF- α during epidermal development and differentiation," *Genes & Development*, # 5:714-727 (1991).
14. Gazit, et al., "Tyrphostins. 6. Dimeric Benzylidenemalononitrile Tyrphostins: Potent Inhibitors of EGF Receptor Tyrosine Kinase *in Vitro*," *Journal of Medicinal Chemistry*, # 39:4905-4911 (1996).
15. Ben-Bassat, et al., "Tyrphostins suppress the growth of psoriatic keratinocytes," *Experimental Dermatology*, # 4:82-88 (1995).
16. Panek, et al., "*In Vitro* Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor," *The Journal of Pharmacology and Experimental Therapeutics*, # 283 (3):1433-1444 (1997).
17. Abgenix, Inc. Press Release, "Abgenix Initiates Phase III Clinical Trial with ABX-IL8 in Psoriasis," April 3, 2000.

The above-referenced documents are listed on PTO Form 1449. Copies of the cited documents are enclosed to facilitate reference to them.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,



James F. Harrington
Registration No.: 44,741
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
JFH/jp

115479_1.DOC

Docket Number: 381-86

JC841 U.S. PTO
09/635974

09/09/00

**TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH
EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS**

Invented by:

Thomas Teufel

Patent Application Prepared By:

James F. Harrington
Registration No. 44,741
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550